April 18, 2017

First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the enrollment of the first patient recruited in the COMPETE study, an international pivotal multi-center phase III clinical...

Full releases >>

August 04, 2016

ITM´s subsidiary ITG receives Drug Approval for EndolucinBeta®

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope...

Full releases >>

May 10, 2016

EMA/CHMP adopts positive opinion for ITM’s EndolucinBeta®

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive...

Full releases >>

March 24, 2016

ITM and Scil Proteins announce new Partnership for Targeted Radio Conjugates

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and targeted carriers, today announced they have entered into a partnership covering...

Full releases >>

March 07, 2016

ITM announces successful fundraising of 20 million EUR

Clinical development of Targeted Radionuclide Therapies to get major boost Investment will support growth initiatives of the company

Full releases >>

August 18, 2015

Isotope Technologies Garching GmbH announces in- licensing of DOTA-Zoledronate for Bone Targeted Radionuclide Theranostics of Osseous Metastases

The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone Targeted Radionuclide Therapy and Diagnostics in patients suffering from bone...

Full releases >>